Skip to main content

Table 2 Overall survival rates and cumulative incidences of mortality among SEER patients with cNET

From: Construction and validation of the prognostic model for patients with neuroendocrine cervical carcinoma: a competing risk nomogram analysis

Characteristic

Patients

Overall survival rate (%)

P

Cancer-specific mortality (%)

P

Non-cancer-specific mortality (%)

P

No

(%)

1 year

3 year

5 year

1 year

2 year

3 year

1 year

2 year

3 year

Total

894

100

69.2

45.5

41.9

 

24.6

44.3

46.9

 

6.1

10.1

11.1

 

Age(years)

  < 44

372

41.6

85.0

61.8

60.0

 < 0.001

13.6

35.7

37.5

 < 0.001

1.3

2.5

2.6

 < 0.001

  45–67

377

42.2

62.5

38.9

34.4

 

30.2

49.5

52.9

 

7.2

11.5

12.7

 

   > 67

145

16.2

46.5

20.8

15.2

 

38.2

53.1

55.9

 

15.2

26.1

28.8

 

Year

 2004–2009

432

48.3

72.5

49.4

45.5

0.025

22.1

41.9

44.4

0.096

5.3

8.6

10.1

0.353

 2010–2015

462

51.7

66.1

41.4

38.4

 

27.1

46.7

49.7

 

6.8

11.8

11.9

 

Marital Status

 Married

348

38.9

77.3

52.7

48.4

 < 0.001

19.1

40.2

43.9

0.064

3.4

7.1

7.5

 < 0.001

 Single

401

44.9

66.4

42.8

41.2

 

28.3

48.6

49.9

 

5.3

8.5

8.9

 

 Other

145

16.2

57.7

35.6

28.9

 

27.7

42.7

46.1

 

14.5

21.6

25.1

 

Racea

 White

636

71.1

70.8

47.9

43.6

0.002

22.9

41.9

45.1

0.025

6.2

10.2

11.3

0.843

 Black

148

16.6

62.8

34.7

32.1

 

29.8

54.3

56.0

 

7.4

10.9

11.9

 

 Other1

110

12.3

68.7

46.1

45.4

 

27.6

45.0

45.2

 

3.6

8.8

8.9

 

Gradeb

 Low

58

6.5

89.7

82.4

80.5

 < 0.001

8.6

15.8

15.9

 < 0.001

1.7

1.8

1.9

0.008

 High

836

93.5

67.8

42.8

38.9

 

25.8

46.4

49.2

 

6.4

10.7

11.8

 

FIGO Stage

 I

411

46.0

89.1

70.0

65.7

 < 0.001

8.4

24.6

27.3

 < 0.001

2.4

5.3

6.9

 < 0.001

 II

212

23.7

72.2

35.4

32.9

 

20.6

50.3

52.8

 

7.1

14.2

14.3

 

 III

200

22.4

42.0

18.4

14.5

 

48.9

68.2

72.1

 

9.1

13.4

13.5

 

 IV

71

7.9

22.5

4.8

0

 

61.9

76.7

76.8

 

15.5

18.4

10.8

 

Tumor Size

 < 2

196

22.0

94.8

84.9

82.8

 < 0.001

4.1

12.4

13.1

 < 0.001

1.1

2.6

4.1

0.001

 2–4

172

19.2

80.7

50.3

44.5

 

15.2

41.5

44.8

 

4.1

8.1

10.6

 

 > 4

526

58.8

56.0

28.9

25.4

 

35.3

57.4

60.6

 

8.6

13.6

13.9

 

Metastasis

 Absent

643

71.9

82.4

58.8

54.8

 < 0.001

12.2

31.6

34.5

 < 0.001

5.3

9.5

10.6

0.418

 Present

251

28.1

35.3

11.0

8.2

 

56.6

77.2

79.3

 

8.1

11.7

12.4

 

Surgery

 Performed

413

46.2

88.2

67.1

63.1

 < 0.001

9.8

29.3

32.5

 < 0.001

1.9

3.5

4.2

 < 0.001

 None

481

53.8

52.9

26.4

23.1

 

37.4

57.5

59.6

 

9.6

16.1

17.2

 

Radiotherapy

 Yes

347

38.8

72.1

55.3

52.9

 < 0.001

21.2

35.2

36.7

 < 0.001

6.6

9.4

10.2

0.380

 No

547

61.2

67.4

38.8

34.3

 

26.8

50.4

53.9

 

5.7

10.6

11.7

 

Chemotherapy

 Yes

577

64.5

71.9

40.6

35.7

0.018

24.2

51.2

55.4

 < 0.001

3.8

8.1

8.9

0.006

 No

317

35.5

64.4

53.3

51.8

 

25.4

32.7

33.1

 

10.2

13.9

15.1

 
  1. aAmerican Indian/Alaskan Native, Asian/Pacific Islander, bLow: Grade I (well differentiated) and Grade II (moderately differentiated); High: Grade III (poorly differentiated) and Grade IV(undifferentiated anaplastic)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us